An Observational Study of Subcutaneous Implantable Cardioverter Defibrillator in Patients with Hypertrophic Cardiomyopathy At High Risk of Sudden Cardiac Death
HCM - Hypertrophic CardiomyopathyS-ICD System (implantable Defibrillator)
Study summary
1. To observe the failure rate of S-ICD screening in HCM patients at high risk of SCD.
2. To observe the incidence of IAS in HCM patients with S-ICD implantation and explore the related factors of IAS.
Eligibility
Sex
ALL
Min age
14 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* HCM patients assessed as meeting the ICD implantation indication
Exclusion Criteria:
* Combined with bradycardia with pacing indications;
* Frequent monomorphic ventricular tachycardia require ATP therapy;
* With indications of CRT;
* Combined with other diseases, life expectancy is less than 1 year.
Primary outcome measure(s)
the failure rate of S-ICD screening — 3 months S-ICD screening failed
The inappropriate shock event — 3 months The incidence of inappropriate shock event
Trial sites (1)
Facility
City
Region
Status
Fuwai hospital
Beijing
China
More China National Center for Cardiovascular Diseases trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.